PMID- 23238593
OWN - NLM
STAT- MEDLINE
DCOM- 20130903
LR  - 20130214
IS  - 1476-5500 (Electronic)
IS  - 0929-1903 (Linking)
VI  - 20
IP  - 2
DP  - 2013 Feb
TI  - TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious 
      diseases.
PG  - 65-9
LID - 10.1038/cgt.2012.87 [doi]
AB  - A vaccine platform has been created by attaching the target-associated antigen 
      (TAA) for the vaccine to the extracellular domain (ecd) of the potent 
      immunostimulatory signal CD40 ligand (CD40L). Attachment of the TAA to the CD40L 
      promotes uptake of the TAA into dendritic cells (DCs), binding to Class I as well 
      as Class II MHC leading to presentation of the TAA on the DCs, expansion of the 
      TAA-specific B cell and CD8 effector T-cell lymphocytes, and induction of a 
      memory response. In addition, the TAA/ecdCD40L vaccine can overcome anergy, 
      induce regressions of pre-existing subcutaneous (SC) nodules of cancer cells, and 
      induce high titers of neutralizing antibodies against viral antigens. This 
      vaccine, which can be administered SC as a TAA/ecdCD40L fusion protein, or as 
      expression vectors (viral or plasmid) or as a vector prime-protein boost 
      strategy, is applicable to the development of vaccine for a wide range of cancers 
      and infectious agents.
FAU - Deisseroth, A
AU  - Deisseroth A
AD  - MicroVAX LLC, Mason Enterprise CTR, Manassas, VA 20110-281, USA. 
      albert.deisseroth@yahoo.com
FAU - Tang, Y
AU  - Tang Y
FAU - Zhang, L
AU  - Zhang L
FAU - Akbulut, H
AU  - Akbulut H
FAU - Habib, N
AU  - Habib N
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20121214
PL  - England
TA  - Cancer Gene Ther
JT  - Cancer gene therapy
JID - 9432230
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 147205-72-9 (CD40 Ligand)
SB  - IM
MH  - Adenoviridae/genetics
MH  - Adjuvants, Immunologic/administration & dosage
MH  - Antigens, Neoplasm/genetics/*immunology
MH  - CD40 Ligand/administration & dosage/genetics/*immunology
MH  - CD8-Positive T-Lymphocytes/cytology/immunology
MH  - Cancer Vaccines/administration & dosage/genetics/*immunology
MH  - Communicable Diseases/*drug therapy/immunology
MH  - Dendritic Cells/cytology/immunology
MH  - Genetic Vectors
MH  - Humans
MH  - Neoplasms/*drug therapy/immunology
EDAT- 2012/12/15 06:00
MHDA- 2013/09/04 06:00
CRDT- 2012/12/15 06:00
PHST- 2012/12/15 06:00 [entrez]
PHST- 2012/12/15 06:00 [pubmed]
PHST- 2013/09/04 06:00 [medline]
AID - cgt201287 [pii]
AID - 10.1038/cgt.2012.87 [doi]
PST - ppublish
SO  - Cancer Gene Ther. 2013 Feb;20(2):65-9. doi: 10.1038/cgt.2012.87. Epub 2012 Dec 
      14.